Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Clinical trial NCT01211457 · UNKNOWN
Trial details
- NCT number
- NCT01211457
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-06-17
- Primary completion
- 2020-06-20
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.